1. Home
  2. HRTG vs CBIO Comparison

HRTG vs CBIO Comparison

Compare HRTG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heritage Insurance Holdings Inc.

HRTG

Heritage Insurance Holdings Inc.

HOLD

Current Price

$34.42

Market Cap

670.9M

Sector

Finance

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$19.26

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRTG
CBIO
Founded
2012
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
670.9M
537.5M
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
HRTG
CBIO
Price
$34.42
$19.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$33.50
$26.67
AVG Volume (30 Days)
232.5K
242.1K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
214.43
N/A
EPS
3.23
N/A
Revenue
$847,330,000.00
$18,500.00
Revenue This Year
$7.50
N/A
Revenue Next Year
$6.74
$279.20
P/E Ratio
$10.54
N/A
Revenue Growth
3.71
N/A
52 Week Low
$20.48
$8.72
52 Week High
$36.50
$27.41

Technical Indicators

Market Signals
Indicator
HRTG
CBIO
Relative Strength Index (RSI) 59.15 57.80
Support Level $25.34 $16.65
Resistance Level $36.06 $21.14
Average True Range (ATR) 1.03 1.31
MACD -0.22 0.25
Stochastic Oscillator 43.11 54.44

Price Performance

Historical Comparison
HRTG
CBIO

About HRTG Heritage Insurance Holdings Inc.

Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: